Novo Nordisk (NVO) and Eli Lilly & Co. (NYSE:LLY), the global leaders in obesity medications, are now facing their first ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...

Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging ...

The US Food and Drug Administration (FDA) has granted approval for a label update to Eli Lilly and Company's Amyvid ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

This week's dividend activity included increased payouts from General Mills (GIS) and Worthington Enterprises (WOR) as well ...

Citi stated that as the obesity space evolves from injectables to convenient orals, such as orforglipron, the emergence of a ...

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

Proponents say direct-to-consumer sales by drugmakers cut out intermediaries that add needlessly to prices. Detractors see ...

Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities ...